Clinical and Experimental Nephrology

, Volume 14, Issue 5, pp 445–452 | Cite as

Incidence of symptomatic stroke and cancer in chronic kidney disease patients treated with epoetins

  • Enyu Imai
  • Ryohei Yamamoto
  • Hiromichi Suzuki
  • Tsuyoshi Watanabe
Original Article

Abstract

Background

Use of erythropoiesis-stimulating agents (ESA) has been reported to increase the incidence of cardiovascular diseases at target Hb levels by more than 12.0 g/dl. The recent TREAT study found an increased incidence of stroke and cancer when maintaining the Hb level at 12.5 g/dl in diabetic patients.

Methods

Surveillance of Epoetin-Adverse Events of Stroke and Cancer (SEASCAN) was a cross-sectional study conducted under urgent conditions by the Committee on CKD Initiatives of the Japanese Society of Nephrology. Patients who were at least 18 years old and had CKD stage 4 and 5, namely, eGFR <30 ml/min/1.73 m2, and who had visited the outpatient department of the participating facilities between December 2009 and January 2010 with at least 6 months of prior medical treatment in the participating facilities were eligible to participate in the study.

Results

Of 7,415 patients with CKD stage 4 and 5, 3,653 (49.3%), 879 (11.9%) and 2,883 (38.9%) patients received no epoetin, epoetin for less than 6 months and epoetin for at least 6 months, respectively. In patients who did not use epoetin, use of epoetin for less than 6 months and use of epoetin for at least 6 months, the numbers of patients with stroke were 38 (1.0%), 8 (0.9%) and 27 (0.9%), respectively, and those with newly diagnosed or exacerbated malignancy were 88 (2.4%), 30 (3.4%) and 71 (2.5%), respectively, demonstrating insignificant associations between outcome and duration of treatment with epoetin (P for trend = 0.666 in stroke and 0.836 in malignancy).

Conclusions

No significant increase in the risk of developing symptomatic stroke and cancer was observed for the use of epoetin in current clinical practice in Japan.

Keywords

Renal anemia Stroke Cancer CKD Japanese 

References

  1. 1.
    Sliverberg D, Wexler D, Blum M, et al. The cardio-renal-anemia syndrome: does it exist? Nephrol Dial Transplant. 2003;18(Supple 8):viii7–12.Google Scholar
  2. 2.
    Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004;19(1):121–32.CrossRefPubMedGoogle Scholar
  3. 3.
    Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28(1):53–61.CrossRefPubMedGoogle Scholar
  4. 4.
    JSDT. Guideline for renal anemia in chronic kidney disease. Japanese of Japanese Society for Dialysis Therapy. 2008;41:661–716.CrossRefGoogle Scholar
  5. 5.
    European Best Practice guideline working group. European best practice guideline for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(Supple 2):S1–47.Google Scholar
  6. 6.
    KDOQI. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(Supple 3):S1–144.Google Scholar
  7. 7.
    Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019–32.CrossRefPubMedGoogle Scholar
  8. 8.
    Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2009;13:621–30.CrossRefPubMedGoogle Scholar
  9. 9.
    Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92.CrossRefPubMedGoogle Scholar
  10. 10.
    Cuzick J. A Wilcoxon-type test for trend. Stat Med. 1985;4(1):87–90.CrossRefPubMedGoogle Scholar
  11. 11.
    Prevalence of stroke in Japanese general population. http://www.mhlw.go.jp/toukei/kouhyo/data-kou18/data12/junkan-h12-2.pdf. Accessed 25 April 2010.
  12. 12.
    Kokubo Y, Nakamura S, Okamura T, Yoshimasa Y, Makino H, Watanabe M, et al. Relationship between blood pressure category and incidence of stroke and myocardial infarction in an urban Japanese population with and without chronic kidney disease: the Suita Study. Stroke. 2009;40(8):2674–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Inoue R, Ohkubo T, Kikuya M, Metoki H, Asayama K, Kanno A, et al. Stroke risk of blood pressure indices determined by home blood pressure measurement: the Ohasama study. Stroke. 2009;40(8):2859–61.CrossRefPubMedGoogle Scholar
  14. 14.
    Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–98.CrossRefPubMedGoogle Scholar
  15. 15.
    Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071–84.CrossRefPubMedGoogle Scholar
  16. 16.
    Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111(12):992–1000.PubMedGoogle Scholar
  17. 17.
    Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J. 1990;300(6724):573–8.CrossRefGoogle Scholar
  18. 18.
    Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74(6):791–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Hirakata H, Tsubakihara Y, Gejyo F, Nishi S, Iino Y, Watanabe Y, et al. Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients. Clin Exp Nephrol. 2010;14(1):28–35.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2010

Authors and Affiliations

  • Enyu Imai
    • 1
  • Ryohei Yamamoto
    • 2
  • Hiromichi Suzuki
    • 3
  • Tsuyoshi Watanabe
    • 4
  1. 1.Department of NephrologyNagoya University Graduate School of MedicineNagoyaJapan
  2. 2.Department of Geriatric Medicine and NephrologyOsaka University Graduate School of MedicineSuitaJapan
  3. 3.Department of NephrologySaitama Medical UniversitySaitamaJapan
  4. 4.Third Department of MedicineFukushima Medical CollegeFukushimaJapan

Personalised recommendations